Sanofi's CEO Paul Hudson revealed that the company integrates AI recommendations into its drug development decision process, using machine insights to guide progression through clinical phases. Emphasizing AI’s impartiality, Hudson highlighted that AI lacks personal stakes, making its guidance 'sobering' but dispassionate. The pharmaceutical giant has incorporated AI over the past three years in discovery phases, aiming to optimize resource allocation amidst lengthy drug development cycles and high R&D costs. Industry leaders at Davos similarly advocated for embracing AI-driven approaches in life sciences innovation.